Speakers: Julie Bailis, Amgen; Chi-Chung Li; Laurence Fayadat-Dilman, Merk; Tim Jacobs, Abcellera; Siddharth Sukumaran ,Janssen; Genevive Hernandez, IGM Biosciences; Xiling Jiang, FDA
Organizers: Chi-Chung Li (Genentech); Ayse Meric Ovacik (Genentech); Betty Chang (Summit Therapeutics); Yao Yu (Merck)
Date: 2022-11-02- 11/03/2022
Time: 8:30-11:45 Pacific Time
Registration fee: Free
Location: Online via zoom
Major Sponsor:
Vendor show vendors registered to date:
Registration: http://www.PBSS.org
Registration deadline:2022-10-30  (it will close sooner if the seating cap is reached)

About the Topic

T cell-engaging bispecific antibodies (TDB) are becoming important molecular entities in the development of immune-oncology agents.  TDBs work through the direct binding to the T cells and target tumor cells, and thereby creating an immune synapse which activates the T cells leading to the release of cytotoxic granules for tumor killing.  This novel modality and mechanism of action pose unique opportunities and challenges for drug discovery and development.  In this workshop, we will provide an overview of discovery and development of TDBs through invited presentations by experts in the field.  Day 1 focuses on discovery/preclinical development and Day 2 focuses on clinical development of T-Cell engaging bispecifics. There will be a panel discussion at the end of each day.

Note: This is an online meeting, The Zoom link will be sent to the registrants 1+ days before the event.

Nov. 2nd Agenda

Nov. 3rd Agenda